证券代码：002044 证券简称：美年健康 公告编号：2026-011 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2025 年 12 月 16 日召开第九届董事会第十六次（临时）会议及 2026 年 1 月 6 日召开 2026 年第一次临时股东会，审议通过《关于公司及下属子公司申请融资额度并提供担 保的议案》，同意公司及部分下属子公司 2026 年度为公司及合并报表范围内的子 公司提供担保额度累计不超过人民币 53 亿元。具体内容详见公司于 2025 年 12 月 17 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及下属子公司申请融 资额度并提供担保的公告》（公告编号：2025-086）。 二、进展情况 近日，公司全资子公司美年大健康产业（集团）有限公司（以下简称"美年大 健康"）向招商银行股份有限公司上海分行（以下简称"招商银行上海分行"）签署 了《最高额不可撤销担保书》 ...

中国医药 中国医药 - 招银国际环球市场 | 睿智投资 | 行业研究 高端化和 AI 技术驱动中国体检行业长期增长 在中国人口老龄化不断加剧和居民健康意识不断提升的背景下，中国体检行业的市 场规模维持了快速增长趋势。根据中研普华的数据，中国体检行业规模在 2020 至 2024 年的年复合增长率（CAGR）为 9.2%，预计在 2024 至 2030 年将以 18.3%的 CAGR加速增长。中国体检渗透率约为 40%，远低于发达国家的 70%，意味着持续 增长的空间广阔。当前体检市场呈现"公立主导、民营追赶"的鲜明格局。根据前 瞻产业研究院的数据，公立医院占据 69%的市场份额，而民营机构的市占率提升至 24%。头部民营体检机构包括美年健康（002044 CH，未评级）、爱康国宾（未上 市）以及瑞慈医疗（1526 HK，未评级）。中国体检行业呈现出显著的高端化趋 势，头部民营体检机构均大力发展高端业务，助力提升ASP和利润率。此外，AI 技 术正成为中国体检行业突破传统瓶颈、实现高质量发展的核心引擎，而具备数据与 场景优势的龙头有望持续拉开与中小连锁的竞争身位。 2026 年 2 月 5 日 中国 医药 行业 ...

Group 1 - The company, through its wholly-owned subsidiary Meinian Chuangxin, has acquired a 16.6667% limited partnership interest in the Guangzhou Qiaoxin Shengjing No. 1 Venture Capital Partnership from Guangzhou Huacheng Shucai Information Technology Co., Ltd. for a subscribed capital of RMB 10 million, with no actual payment made yet [1] - The total subscribed capital for the partnership amounts to RMB 60 million, with Meinian Chuangxin contributing RMB 10 million, representing 16.6667% of the total [1] - The partnership agreement was signed with several other investment firms, including Guangzhou Shengjing Venture Capital Co., Ltd. and Sichuan Puxin Industrial Financial Investment Co., Ltd. [1] Group 2 - The fund manager, Shengjing Venture Capital, has completed the registration process with the Asset Management Association of China and obtained the Private Fund Registration Certificate for the Guangzhou Qiaoxin Shengjing No. 1 Venture Capital Partnership [2] - The fund's registration code is SBMR23, and it was officially registered on February 2, 2026 [2] - The fund has completed the business change registration as of the announcement date, and the company will comply with relevant regulations during the investment process [2]

证券代码：002044 证券简称：美年健康 公告编号：2026-010 美年大健康产业控股股份有限公司 关于下属全资子公司受让股权投资基金份额 暨与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 美年大健康产业控股股份有限公司（以下简称"公司"）下属全资子公司美年 创信（上海）企业管理有限公司（以下简称"美年创信"）与广州华诚数财信息科 技有限公司（以下简称"华诚数财"）签署了《广州侨鑫胜璟一号创业投资合伙企 业（有限合伙）份额转让协议书》，受让华诚数财所持有的广州侨鑫胜璟一号创 业投资合伙企业（有限合伙）（以下简称"胜璟一号基金"）16.6667%的有限合伙 份额，对应的认缴出资额为人民币 1,000 万元，实缴出资额为人民币 0 元。同时， 美年创信与广州胜璟创业投资有限公司（以下简称"胜璟创投"）、四川璞信产融 投资有限责任公司、佛山市三水区金融投资控股有限公司、侨银城市管理股份有 限公司、华诚数财签署了《广州侨鑫胜璟一号创业投资合伙企业（有限合伙）之 合伙协议》，约定共同投资胜璟一号基金， ...

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Core Viewpoint - Meinian Health is seeking to participate in the pre-restructuring of Bangjie Holdings, aiming to gain control of a company heavily in debt due to its foray into the photovoltaic industry, raising questions about the strategic rationale behind this move [1] Group 1: Meinian Health's Financial Performance - Meinian Health reported a total revenue of 10.702 billion yuan in 2024, a year-on-year decrease of 1.76% [1] - The net profit attributable to shareholders was 282 million yuan, down 44.18% year-on-year [1] - The company's gross margin was 42.78%, a slight decrease of 0.01 percentage points, while the net margin fell to 3.82%, a decrease of 37.75% year-on-year [1] - The decline in performance is attributed to a reduction in the number of health check-ups and intensified industry competition [1] Group 2: Debt Structure and Financial Health - As of the end of Q3 2025, Meinian Health had cash and cash equivalents of 2.011 billion yuan, with short-term borrowings and current liabilities exceeding 3.9 billion yuan [1] - The company’s interest-bearing debt reached 6.338 billion yuan, continuing to rise slightly year-on-year [1] - The high debt levels contrast sharply with the company's weak profitability, indicating insufficient financial flexibility [1] Group 3: Bangjie Holdings' Financial Troubles - Bangjie Holdings, originally focused on seamless clothing, invested over 10 billion yuan in the photovoltaic sector starting in 2022, but faced severe challenges due to price wars and tightened financing [2] - The company announced the termination of an 8 billion yuan photovoltaic project and has accumulated overdue debts totaling 969 million yuan [2] - As of the end of Q3 2025, Bangjie Holdings had a debt-to-asset ratio of 138.88%, with cash reserves of only 150 million yuan against interest-bearing debts of 1.9 billion yuan [2] - The company has incurred cumulative losses exceeding 1.6 billion yuan from 2023 to Q3 2025, with a net loss of 672 million yuan in 2024 and 905 million yuan in the first three quarters of 2025 [2] Group 4: Risks and Challenges of the Acquisition - Meinian Health's participation in Bangjie Holdings' restructuring may require significant capital investment to settle debts and restore operations, which could strain its own liquidity [2][3] - The ongoing losses from Bangjie Holdings' photovoltaic business and outstanding debts may negatively impact Meinian Health's overall profitability even after restructuring [3] - Meinian Health faces management challenges due to a lack of operational experience in the photovoltaic sector, compounded by the uncertainties surrounding Bangjie Holdings' assets [3] Group 5: Industry Analyst Insights - Industry analysts suggest that the photovoltaic sector is not a reliable lifeline for Meinian Health, as latecomers lack cost advantages, and halting production may be the only viable option for Bangjie Holdings [4] - The high-risk nature of this cross-industry acquisition is underscored by Meinian Health's own financial pressures and Bangjie Holdings' significant debt and ongoing losses [4] - The success of this "cross-industry marriage" will depend on the design of the restructuring plan and Meinian Health's ability to maintain its financial safety while supporting the new business [4]

Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]

登录新浪财经APP 搜索【信披】查看更多考评等级 美年大健康产业控股股份有限公司 第九届董事会 证券代码：002044 证券简称：美年健康 公告编号：2026-008 第十七次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十七次（临时）会议于2026年1 月23日以电子发送等形式发出会议通知，会议于2026年1月29日下午16:35在上海市静安区灵石路697号 健康智谷9号楼四楼公司会议室以现场结合书面审议方式召开。应出席本次会议的董事为9名，实际出席 会议的董事为9名。会议由公司董事长俞熔先生主持，公司部分高级管理人员列席了会议。本次会议的 出席人数、召开表决程序、议事内容均符合《中华人民共和国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 1.审议并通过《关于拟参与浙江棒杰控股集团股份有限公司预重整的议案》 表决结果：赞成9票，反对0票，弃权0票。 公司作为意向投资者参与浙江棒杰控股集团股份有限公司（以下简称"棒杰股份"）重整投资人的公 ...

面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经1月29日讯（记者 陈夏筱）为了拓展业务布局，体检龙头企业美年健康（002044.SZ）计划参 与棒杰股份（002634.SZ）的预重整。 今日晚间，公司发布公告称，公司第九届董事会第十七次会议审议通过了《关于拟参与浙江棒杰控股集 团股份有限公司预重整的议案》，同意公司作为意向投资者参与棒杰股份重整投资人的公开招募，并指 定下属全资子公司美年大健康为重整受让主体取得棒杰股份的控制权，成为棒杰股份重整完成后的控股 股东。 2025年3月1日，棒杰股份扬州工厂宣布全线停工停产，原计划3个月的检修期结束后，工厂再无力复 产。2025年7月，棒杰股份宣布江山光伏项目终止，并向地方政府支付1500万元赔偿款，公司跨界光伏 的努力全面归零。此时，棒杰股份光伏板块逾期债务总额据披露已达9.67亿元。 2025年7月，上海启烁睿行通过受让股份成为公司新控股股东，黄荣耀成为新的实际控制人。 财务数据 ...

Core Viewpoint - Meinian Health (002044.SZ) plans to participate in the pre-restructuring of Bangjie Co., aiming to integrate industry resources and expand its business layout, designating its wholly-owned subsidiary Meinian Health Industry (Group) Co., Ltd. as the entity to gain control of Bangjie Co. after the restructuring [1] Group 1 - The company held its 17th meeting of the 9th Board of Directors to approve the proposal to participate in the pre-restructuring of Zhejiang Bangjie Holdings Group Co., Ltd. [1] - The company will act as an interested investor in the public recruitment of investors for the restructuring of Bangjie Co. [1] - The management is authorized to organize the selection of investors, due diligence, and preparation of the pre-restructuring investment plan [1]